Lumosa Therapeutics (Lumosa; 6535.TWO) today announced positive results from two independent Phase 2 clinical trials with its novel stroke drug LT3001 (Odatroltide). LT3001 is a first-in-class ...
A shopping editor shares 20 budget-friendly products, all under $20, that are vetted by the USA TODAY shopping team and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results